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Background: There is limited long-term data comparing tirofiban, given at high dose bolus (HDB) versus abciximab in patients with ST-segment 
elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). As the benefit of abciximab administration 
versus placebo has been shown to accrue over time, likely reflecting the treatment effect on myocardial salvage, comparing tirofiban versus 
abciximab at long-term follow-up is crucial to assess the effect of these two pharmacological treatments on left ventricular recovery over time and 
subsequent cardiovascular outcomes.
Methods: The MULTISTRATEGY (MULTIcentre evaluation of Single high-dose bolus TiRofiban versus Abciximab with sirolimus eluting sTEnt or Bare 
Metal Stent in Acute Myocardial Infarction studY [MULTISTRATEGY]) is an open-label, 2×2 factorial trial of 745 patients (median age [IQR] 64 [55-
74]) presenting with STEMI or new left bundle-branch block at 16 referral centers in Italy, Spain and Argentina between October 2004 and April 
2007 being randomly allocated to HDB tirofiban vs. abciximab infusion before arterial sheath insertion. At 1 year all patients but four received 
clinical follow-up.
Results: There were cumulatively 14 (3.8%) fatal events in the tirofiban arm versus 17 (4.6%) in the abciximab group (p=0.71). The composite of 
death or myocardial infarction (MI) in the tirofiban group (n=27, 7.3%) did not differ with that observed in patients treated with abciximab (n=30, 
8.1%; p=0.78). The need for target vessel revascularisation (TVR) was also identical in the groups so the cumulatively incidence of major adverse 
cardiovascular events, including death, MI or TVR occurred in 43 patients (11.6%) in the tirofiban arm and 50 individuals (13.4%) in the abcixmab 
arm (p=0.50). Focusing on patients presenting with anterior MI, the 1-year mortality rate was 3.2% in the tirofiban group versus 7.9% in the 
abciximab arm (p=0.09). The incidence of stent thrombosis was similar in the two stent groups.
Conclusions: Tirofiban therapy led to similar cardiovascular outcomes at 1-year follow-up compared to abciximab. This effect appeared to be 
consistent even in high risk patients subsets
